Form 10-Q Celator Pharmaceuticals For: Sep 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Form 10-Q Celator Pharmaceuticals For: Sep 30

Celator Pharmaceuticals (CPXX) Posts Q3 Loss of 21c/Share

November 14, 2014 7:39 AM EST

Celator Pharmaceuticals (NASDAQ: CPXX) reported Q3 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25).

Third Quarter 2014 and Recent Business Highlights:

CPX-351:

In October, Celator announced it had achieved its target enrollment in a Phase 3 clinical study of CPX-351 Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia (AML).In September, Celator announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of CPX-351 and support its ongoing clinical testing in pediatric patients with acute lymphoblastic leukemia... More